A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Kei Muro, MD
Aichi Cancer Center Hospital, Japan
Principal Investigator - Ruihua Xu, MD, PhD
Sun Yat-Sen University Cancer Center, China
Principal Investigator - Tae Won Kim, MD, PhD
ASAN Medical center, South Korea
Principal Investigator - Young Suk Park, MD, PhD
Samsung Medical Center, South Korea
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Npo Epidemiological and Clinical Research Information Network (ecrin)
Kyoto, Japan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Dec 2013
- Primary completion
- 20 Nov 2017
- Completion
- 30 Jun 2018
- Last update posted
- 8 Jan 2019
- Registered enrollment
- 650
- Registry id
- NCT01996306
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.